

# Sarina A Piha-Paul

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2133748/publications.pdf>

Version: 2024-02-01

191  
papers

18,686  
citations

29994

54  
h-index

14702

127  
g-index

197  
all docs

197  
docs citations

197  
times ranked

25463  
citing authors

#	ARTICLE	IF	CITATIONS
1	IFN- $\gamma$ -related mRNA profile predicts clinical response to PD-1 blockade. <i>Journal of Clinical Investigation</i> , 2017, 127, 2930-2940.	3.9	2,560
2	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1-10.	0.8	1,740
3	Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. <i>Lancet Oncology</i> , The, 2020, 21, 1353-1365.	5.1	1,363
4	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1470-1478.	0.8	671
5	T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. <i>Journal of Clinical Oncology</i> , 2019, 37, 318-327.	0.8	656
6	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , 2018, 554, 189-194.	13.7	572
7	Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative. <i>Clinical Cancer Research</i> , 2012, 18, 6373-6383.	3.2	458
8	Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 4035-4041.	0.8	375
9	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 2753-2762.	0.8	372
10	AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer. <i>Science Translational Medicine</i> , 2015, 7, 314ra185.	5.8	352
11	<i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 558-565.	1.9	311
12	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. <i>International Journal of Cancer</i> , 2020, 147, 2190-2198.	2.3	288
13	<i>PIK3CA</i> Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials. <i>Cancer Research</i> , 2013, 73, 276-284.	0.4	262
14	Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. <i>Annals of Oncology</i> , 2018, 29, 1807-1813.	0.6	261
15	Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 61-67.	0.8	259
16	Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. <i>Journal of Thoracic Oncology</i> , 2020, 15, 618-627.	0.5	254
17	Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2804-2811.	3.2	249
18	Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2033-2041.	3.2	224

#	ARTICLE	IF	CITATIONS
19	Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors. <i>Cell Reports</i> , 2014, 6, 377-387.	2.9	210
20	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. <i>Annals of Oncology</i> , 2017, 28, 1036-1041.	0.6	207
21	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. <i>Cancer Research</i> , 2016, 76, 3690-3701.	0.4	203
22	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation. <i>Cancer Discovery</i> , 2016, 6, 1352-1365.	7.7	192
23	Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. <i>Gynecologic Oncology</i> , 2019, 152, 243-250.	0.6	192
24	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. <i>PLoS ONE</i> , 2017, 12, e0189848.	1.1	190
25	<i>BRAF</i> Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i> -Mutant Thyroid Cancer. <i>Thyroid</i> , 2015, 25, 71-77.	2.4	189
26	Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses. <i>Clinical Cancer Research</i> , 2014, 20, 4827-4836.	3.2	186
27	MABp1, a first-in-class true human antibody targeting interleukin-1 in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. <i>Lancet Oncology</i> , The, 2014, 15, 656-666.	5.1	178
28	A Decision Support Framework for Genomically Informed Investigational Cancer Therapy. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	168
29	STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. , 2018, 6, 119.		165
30	Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1764-1771.	0.8	149
31	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. <i>Investigational New Drugs</i> , 2018, 36, 638-646.	1.2	149
32	Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1083-1088.	0.6	145
33	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. <i>Breast Cancer Research</i> , 2019, 21, 78.	2.2	141
34	A Deep Learning Framework for Predicting Response to Therapy in Cancer. <i>Cell Reports</i> , 2019, 29, 3367-3373.e4.	2.9	137
35	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2124-2130.	3.2	132
36	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 181-188.	3.2	127

#	ARTICLE	IF	CITATIONS
37	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. <i>BMC Cancer</i> , 2019, 19, 196.	1.1	126
38	Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz093.	1.4	126
39	Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. , 2017, 5, 100.		114
40	First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 6309-6319.	3.2	114
41	Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. <i>JCO Precision Oncology</i> , 2017, 2017, 1-18.	1.5	107
42	Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification. <i>Annals of Oncology</i> , 2018, 29, 1445-1453.	0.6	103
43	Pembrolizumab for the treatment of programmed death ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. <i>Cancer</i> , 2020, 126, 3021-3030.	2.0	97
44	P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy. <i>Oncotarget</i> , 2013, 4, 705-714.	0.8	96
45	Phase 2 study of pembrolizumab in patients with advanced rare cancers. , 2020, 8, e000347.		95
46	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. <i>Oncotarget</i> , 2015, 6, 12809-12821.	0.8	86
47	Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 198-213.	7.7	83
48	PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes. <i>Oncotarget</i> , 2012, 3, 1566-1575.	0.8	79
49	Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience. <i>Clinical Cancer Research</i> , 2012, 18, 2922-2929.	3.2	78
50	BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1397-1404.	1.9	78
51	TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2475-2485.	1.9	73
52	A phase 1 study of anti-TGF $\beta$ 2 receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 673-680.	1.1	71
53	Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. <i>Investigational New Drugs</i> , 2015, 33, 621-631.	1.2	63
54	Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. <i>Oncotarget</i> , 2017, 8, 39254-39267.	0.8	62

#	ARTICLE	IF	CITATIONS
55	First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 1237-1246.	3.2	61
56	Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2015, 51, 1865-1873.	1.3	60
57	Intratumoral Injection of <i>Clostridium novyi</i> -NT Spores in Patients with Treatment-refractory Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 96-106.	3.2	59
58	Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. , 2017, 5, 35.		58
59	Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. <i>Clinical Cancer Research</i> , 2020, 26, 1247-1257.	3.2	54
60	Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer. <i>Current Pharmaceutical Biotechnology</i> , 2014, 15, 475-485.	0.9	54
61	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of <i>KRAS</i> Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 3657-3666.	3.2	53
62	A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib.. <i>Journal of Clinical Oncology</i> , 2010, 28, 2512-2512.	0.8	52
63	Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. <i>Cancer</i> , 2016, 122, 3401-3409.	2.0	50
64	FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. <i>PLoS ONE</i> , 2014, 9, e89388.	1.1	50
65	Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 495-501.	1.1	46
66	<i>BRAF</i> mutation testing with a rapid, fully integrated molecular diagnostics system. <i>Oncotarget</i> , 2015, 6, 26886-26894.	0.8	45
67	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. <i>Oncotarget</i> , 2016, 7, 67521-67531.	0.8	44
68	Salivary Duct Carcinoma: Targeting the Phosphatidylinositol 3-Kinase Pathway by Blocking Mammalian Target of Rapamycin With Temsirolimus. <i>Journal of Clinical Oncology</i> , 2011, 29, e727-e730.	0.8	43
69	Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. <i>BMC Cancer</i> , 2015, 15, 713.	1.1	43
70	Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and <i>PIK3CA</i> Mutations. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2857-2863.	1.9	42
71	Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. <i>Oncologist</i> , 2021, 26, 588-596.	1.9	42
72	Multiplex <i>KRAS</i> G12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. <i>Annals of Oncology</i> , 2017, 28, 642-650.	0.6	41

#	ARTICLE	IF	CITATIONS
73	Clinical next generation sequencing to identify actionable aberrations in a phase I program. <i>Oncotarget</i> , 2015, 6, 20099-20110.	0.8	41
74	Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. <i>Oncotarget</i> , 2014, 5, 3029-3038.	0.8	40
75	Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. <i>Investigational New Drugs</i> , 2013, 31, 1505-1513.	1.2	36
76	Signature program: a platform of basket trials. <i>Oncotarget</i> , 2018, 9, 21383-21395.	0.8	36
77	Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 446-454.	3.7	36
78	Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 3845-3856.	3.2	35
79	Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. <i>Journal of Hematology and Oncology</i> , 2019, 12, 145.	6.9	35
80	Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 973-977.	1.1	34
81	Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non-“Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2167-2175.	1.9	33
82	Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1681-1694.	3.2	33
83	Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer. <i>Oncotarget</i> , 2013, 4, 118-127.	0.8	33
84	Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. <i>Investigational New Drugs</i> , 2014, 32, 465-472.	1.2	31
85	Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials. <i>Oncotarget</i> , 2013, 4, 153-162.	0.8	31
86	SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	30
87	Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit. <i>Clinical Breast Cancer</i> , 2014, 14, 468-474.	1.1	29
88	Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion. <i>Oncology</i> , 2016, 91, 348-353.	0.9	29
89	Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. <i>Lung Cancer</i> , 2018, 120, 137-141.	0.9	29
90	Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. <i>British Journal of Cancer</i> , 2018, 118, 763-769.	2.9	28

#	ARTICLE	IF	CITATIONS
91	Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. <i>Oncotarget</i> , 2014, 5, 1846-1855.	0.8	28
92	Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I open-label, dose escalation study. <i>International Journal of Cancer</i> , 2022, 150, 993-1006.	2.3	28
93	Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. <i>Cancer</i> , 2014, 120, 2164-2173.	2.0	27
94	Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. <i>British Journal of Cancer</i> , 2018, 118, 1042-1050.	2.9	27
95	A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 918-926.	1.2	26
96	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. <i>JCI Insight</i> , 2017, 2, .	2.3	26
97	Advance Care Planning in Patients With Cancer Referred to a Phase I Clinical Trials Program: The MD Anderson Cancer Center Experience. <i>Journal of Clinical Oncology</i> , 2012, 30, 2891-2896.	0.8	25
98	A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2015, 21, 5235-5244.	3.2	25
99	A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. <i>Investigational New Drugs</i> , 2015, 33, 177-186.	1.2	25
100	A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2021, 27, 3050-3060.	3.2	24
101	Associations between the gut microbiome and fatigue in cancer patients. <i>Scientific Reports</i> , 2021, 11, 5847.	1.6	24
102	Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. <i>Oncotarget</i> , 2016, 7, 23227-23238.	0.8	23
103	Report of the First International Symposium on NUT Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2493-2505.	3.2	23
104	Clinical Use of Precision Oncology Decision Support. <i>JCO Precision Oncology</i> , 2017, 2017, 1-12.	1.5	22
105	Dual EGFR Inhibition in combination with anti-VEGF treatment in colorectal cancer. <i>Oncoscience</i> , 2014, 1, 540-549.	0.9	22
106	Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus. <i>Anticancer Research</i> , 2014, 34, 1939-45.	0.5	22
107	Synthesis of a series of polar, orthogonally protected, $\alpha,\beta$ -disubstituted amino acids. <i>Tetrahedron Letters</i> , 1997, 38, 4013-4016.	0.7	21
108	Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 193-202.	1.1	21

#	ARTICLE	IF	CITATIONS
109	Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors. , 2020, 8, e000870.		21
110	Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit. <i>Oncologist</i> , 2013, 18, 1315-1320.	1.9	20
111	Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. <i>Cancer Medicine</i> , 2016, 5, 3437-3444.	1.3	20
112	Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	20
113	Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. <i>Scientific Reports</i> , 2021, 11, 3667.	1.6	20
114	First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies. <i>Investigational New Drugs</i> , 2021, 39, 1047-1056.	1.2	20
115	First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas. , 2021, 9, e002863.		20
116	Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study. <i>Gynecologic Oncology</i> , 2022, 166, 211-218.	0.6	20
117	Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. <i>Annals of Oncology</i> , 2013, 24, 838-842.	0.6	19
118	Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 700-708.	2.3	19
119	MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e19-e26.	0.9	18
120	Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. <i>Oncologist</i> , 2021, 26, 558-e1098.	1.9	18
121	Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. <i>Investigational New Drugs</i> , 2018, 36, 416-423.	1.2	17
122	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 5579-5587.	3.2	16
123	Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population. <i>Oncotarget</i> , 2013, 4, 772-784.	0.8	16
124	Response of Lymphangioliomyomatosis to a Mammalian Target of Rapamycin Inhibitor (Temsirolimus) -Based Treatment. <i>Journal of Clinical Oncology</i> , 2011, 29, e333-e335.	0.8	15
125	Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report. <i>BMC Dermatology</i> , 2015, 15, 2.	2.1	15
126	PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. <i>ESMO Open</i> , 2021, 6, 100230.	2.0	15



#	ARTICLE	IF	CITATIONS
127	Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study. <i>Oncotarget</i> , 2019, 10, 6526-6535.	0.8	15
128	Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. <i>JCO Precision Oncology</i> , 2022, , .	1.5	15
129	Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. <i>Investigational New Drugs</i> , 2014, 32, 279-286.	1.2	14
130	Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 389-397.	1.1	13
131	Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. <i>Clinical Epigenetics</i> , 2015, 7, 29.	1.8	13
132	Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. <i>Clinical Cancer Research</i> , 2019, 25, 7381-7387.	3.2	13
133	Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e10348.	2.1	13
134	Incidence of Mucositis in Patients Treated With Temsirolimusâ€Based Regimens and Correlation to Treatment Response. <i>Oncologist</i> , 2014, 19, 426-428.	1.9	12
135	Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. <i>Investigational New Drugs</i> , 2015, 33, 700-709.	1.2	12
136	Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. <i>Scientific Reports</i> , 2016, 6, 35448.	1.6	12
137	HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. <i>Human Pathology</i> , 2019, 92, 32-38.	1.1	12
138	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. <i>Npj Precision Oncology</i> , 2021, 5, 21.	2.3	12
139	Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience. <i>Gynecologic Oncology Research and Practice</i> , 2015, 2, 10.	3.6	11
140	Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. <i>Journal of Immunotherapy</i> , 2018, 41, 284-291.	1.2	11
141	Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. , 2020, 8, e000931.		11
142	Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. <i>Experimental Hematology and Oncology</i> , 2020, 9, 7.	2.0	11
143	Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. , 2022, 10, e004822.		11
144	Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic. <i>Clinical Cancer Research</i> , 2014, 20, 5956-5963.	3.2	10

#	ARTICLE	IF	CITATIONS
145	A non-pregnant woman with elevated beta-HCG: A case of para-neoplastic syndrome in ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2016, 17, 49-52.	0.3	10
146	Phase I study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF $\mu$ mutated melanoma and other advanced malignancies. <i>Cancer</i> , 2019, 125, 463-472.	2.0	10
147	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. <i>Scientific Reports</i> , 2020, 10, 3080.	1.6	10
148	The "shield sign" in two men with metastatic salivary duct carcinoma to the skin: cutaneous metastases presenting as carcinoma hemorrhagieoideis. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2012, 5, 27-36.	0.1	10
149	Expanded Analysis of Secondary Germline Findings From Matched Tumor/Normal Sequencing Identifies Additional Clinically Significant Mutations. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	1.5	9
150	PIK3CA, KRAS, and BRAF mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.. <i>Journal of Clinical Oncology</i> , 2010, 28, 2583-2583.	0.8	9
151	Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 33258-33270.	0.8	9
152	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. <i>Oncotarget</i> , 2016, 7, 35132-35143.	0.8	9
153	Factors related to biopsy willingness in patients with advanced cancer in a phase I clinic for molecularly targeted therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 963-970.	1.2	8
154	Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 215-224.	1.2	8
155	Cutaneous Metastasis of a Mucoepidermoid Carcinoma of the Pancreas: First Reported Case. <i>American Journal of Dermatopathology</i> , 2016, 38, 852-856.	0.3	8
156	Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 825-836.	1.1	8
157	Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. <i>Anticancer Research</i> , 2014, 34, 2349-55.	0.5	8
158	Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. <i>Investigational New Drugs</i> , 2015, 33, 911-920.	1.2	7
159	Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 575-581.	1.1	7
160	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. <i>British Journal of Cancer</i> , 2018, 118, 1419-1424.	2.9	7
161	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. <i>Molecular Cancer Research</i> , 2021, 19, 395-402.	1.5	7
162	Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. <i>ESMO Open</i> , 2021, 6, 100079.	2.0	7

#	ARTICLE	IF	CITATIONS
163	Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial. <i>Advances in Therapy</i> , 2021, 38, 4581-4591.	1.3	7
164	Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with <i>BRAF</i> -mutated advanced cancers. <i>Cancer</i> , 2021, 127, 391-402.	2.0	6
165	The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors. <i>Clinical Pharmacokinetics</i> , 2021, 60, 921-930.	1.6	6
166	Quantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301, a nanoparticle of docetaxel. , 2020, 3, 636-646.		6
167	Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1097-1102.	1.1	5
168	Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-14.	1.0	5
169	A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 877-885.	1.1	5
170	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1247-1255.	3.2	5
171	Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. <i>Investigational New Drugs</i> , 2021, 39, 1357-1365.	1.2	5
172	Overview of Ocular Side Effects of Selinexor. <i>Oncologist</i> , 2021, 26, 619-623.	1.9	5
173	Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. <i>Oncotarget</i> , 2017, 8, 33796-33806.	0.8	5
174	Vandetanib photoinduced cutaneous toxicities. <i>Cutis</i> , 2019, 103, E24-E29.	0.4	5
175	Phase I Clinical Trial of Bendamustine and Bevacizumab for Patients With Advanced Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 194-203.	2.3	4
176	Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. <i>Clinical Cancer Research</i> , 2017, 23, 4155-4162.	3.2	4
177	Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors. <i>Experimental Hematology and Oncology</i> , 2021, 10, 59.	2.0	4
178	Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. <i>Oncology</i> , 2017, 92, 14-20.	0.9	3
179	Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study. <i>Investigational New Drugs</i> , 2022, 40, 290-299.	1.2	3
180	A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies. <i>Oncotarget</i> , 2020, 11, 1235-1243.	0.8	3

#	ARTICLE	IF	CITATIONS
181	A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations. <i>Investigational New Drugs</i> , 2021, 39, 1324-1334.	1.2	2
182	A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3037-3049.	1.0	2
183	Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. <i>Investigational New Drugs</i> , 2022, 40, 124-133.	1.2	2
184	Factors affecting symptom presentation in an early-phase clinical trials clinic patient population. <i>Investigational New Drugs</i> , 2020, 38, 1166-1174.	1.2	1
185	Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. <i>ESMO Open</i> , 2020, 5, e001073.	2.0	1
186	Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e16-e24.	0.9	1
187	An umbrella protocol for histology-independent, phase I modular study based on EGFR mutation status: Using erlotinib alone or in combination with cetuximab, bortezomib, or dasatinib to overcome resistance.. <i>Journal of Clinical Oncology</i> , 2011, 29, 2536-2536.	0.8	1
188	Reply to L.D. Locati et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 672-673.	0.8	0
189	A phase I study of ixazomib and erlotinib in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2021, , 1.	1.2	0
190	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. <i>Oncotarget</i> , 2017, 8, 87163-87173.	0.8	0
191	Efficacy of Pembrolizumab in Patients with Advanced Rare Cancers. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0